Pulmonary vaccine delivery: A realistic approach?

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 5, 2012, Pages 249-260

  Tonnis, Wouter F ^a   Kersten, Gideon F ^b   Frijlink, Henderik W ^a   Hinrichs, Wouter L J ^a   De Boer, Anne H ^a   Amorij, Jean Pierre ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Adjuvant; Deposition; Infection; Inhaler; Intervention; Pneumonia

Indexed keywords

ACETYLSALICYLIC ACID; BACTERIAL VACCINE; BCG VACCINE; EDMONSTEN ZAGREB VACCINE; FLAGELLIN VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFLUENZA VACCINE; LIPOPOLYSACCHARIDE VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ANTIGEN PRESENTING CELL; ARTHRALGIA; ARTICLE; CHILL; CONJUNCTIVITIS; COUGHING; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY DEPOSITION; DRY POWDER; DYSPNEA; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INJECTION SITE PAIN; MALAISE; NONHUMAN; PATHOGENESIS; PHARYNGITIS; RHINITIS; VACCINATION; XEROSTOMIA;

ADMINISTRATION, INHALATION; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; VACCINATION; VACCINES;

EID: 84867072460     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0931     Document Type: Article

References (65)

1. Giudice EL, and Campbell JD: Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006;58:68-89.
2. Kersten G, and Hirschberg H: Antigen delivery systems. Expert Rev Vaccines. 2004;3:453-462.
3. Sou T, Meeusen EN, de Veer M, Morton DA, Kaminskas LM, and McIntosh MP: New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol. 2011;29: 191-198.
4. Blank F, Stumbles P, and von Garnier C: Opportunities and challenges of the pulmonary route for vaccination. Expert Opin Drug Deliv. 2011;8:547-563.
5. Liew FY, Russell SM, Appleyard G, Brand CM, and Beale J: Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol. 1984;14:350-356.
6. Amorij JP, Hinrichs WL, Frijlink HW, Wilschut JC, and Huckriede A: Needle-free influenza vaccination. Lancet Infect Dis. 2010;10:699-711.
7. Tumpey TM, Renshaw M, Clements JD, and Katz JM: Mucosal delivery of inactivated influenza vaccine induces Bcell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol. 2001;75:5141-5150.
8. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S, Kurata T, and Sata T: Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol. 2004;74:328-335.
9. Daltro P, Santos EN, Gasparetto TD, Ucar ME, and Marchiori E: Pulmonary infections. Pediatr Radiol. 2011;41(Suppl 1):S69-S82.
10. Ruuskanen O, Lahti E, Jennings LC, and Murdoch DR: Viral pneumonia. Lancet. 2011;377:1264-1275.
11. Tucker SN, Tingley DW, and Scallan CD: Oral adenoviralbased vaccines: historical perspective and future opportunity. Expert Rev Vaccines. 2008;7:25-31.
12. Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, and Collins PL: Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med. 2011;5:515-526.
13. Schmidt AC: Progress in respiratory virus vaccine development. Semin Respir Crit Care Med. 2011;32:527-540.
14. Breiman RF, Butler JC, and McInnes PM: Vaccines to prevent respiratory infection: opportunities on the near and far horizon. Curr Opin Infect Dis. 1999;12:145-152.
15. Caramori G, Ito K, Contoli M, Di Stefano A, Johnston SL, Adcock IM, and Papi A: Molecular mechanisms of respiratory virus-induced asthma and COPD exacerbations and pneumonia. Curr Med Chem. 2006;13:2267-2290.
16. Johnson AW, Osinusi K, Aderele WI, Gbadero DA, Olaleye OD, and Adeyemi-Doro FA: Etiologic agents and outcome determinants of community-acquired pneumonia in urban children: a hospital-based study. J Natl Med Assoc. 2008;100: 370-385.
17. Castaneda-Orjuela C, Alvis-Guzman N, Paternina AJ, and De la Hoz-Restrepo F: Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Vaccine. 2011;29:7644-7650.
18. Linchevski I, Klement E, and Nir-Paz R: Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions - Systematic review and meta-analysis. Vaccine. 2009;27: 2437-2446.
19. Doring G: Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. Int J Med Microbiol. 2010;300:573-577.
20. Stenger RM, Smits M, Kuipers B, van Gaans-van den Brink J, Poelen M, Boog CJ, and van Els CA: Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. Vaccine. 2010;28:6637-6646.
21. Behr MA: BCG - different strains, different vaccines? Lancet Infect Dis. 2002;2:86-92.
22. Gidding HF, Wallace C, Lawrence GL, and McIntyre PB: Australia's national Q fever vaccination program. Vaccine. 2009;27:2037-2041.
23. Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, and Vanbever R: The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology. 2007;122:316-325.
24. Amorij JP, Saluja V, Petersen AH, Hinrichs WL, Huckriede A, and Frijlink HW: Pulmonary delivery of an inulinstabilized influenza subunit vaccine prepared by sprayfreeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007;25:8707-8717.
25. Patton JS, and Byron PR: Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67-74.
26. de Swart RL, LiCalsi C, Quirk AV, van Amerongen G, Nodelman V, Alcock R, Yuksel S, Ward GH, Hardy JG, Vos H, Witham CL, Grainger CI, Kuiken T, Greenspan BJ, Gard TG, and Osterhaus AD: Measles vaccination of macaques by dry powder inhalation. Vaccine. 2007;25:1183-1190.
27. de Swart RL, Kuiken T, Fernandez-de Castro J, Papania MJ, Bennett JV, Valdespino JL, Minor P, Witham CL, Yuksel S, Vos H, van Amerongen G, and Osterhaus AD: Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine. 2006;24:6424-6436.
28. O'Hagan DT, and Valiante NM: Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2003;2:727-735.
29. Singh M, and O'Hagan DT: Recent advances in vaccine adjuvants. Pharm Res. 2002;19:715-728.
30. Thomas C, Gupta V, and Ahsan F: Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res. 2010;27:905-919.
31. Thomas C, Rawat A, Hope-Weeks L, and Ahsan F: Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol Pharm. 2011;8:405-415.
32. De Koker S, Naessens T, De Geest BG, Bogaert P, Demeester J, De Smedt S, and Grooten J: Biodegradable polyelectrolyte microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary delivery. J Immunol. 2010;184:203-211.
33. Curtis MM, and Way SS: Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009;126:177-185.
34. Palm NW, and Medzhitov R: Antifungal defense turns 17. Nat Immunol. 2007;8:549-551.
35. Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, and Drane D: Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol Cell Biol. 2009;87:371-376.
36. Wee JL, Scheerlinck JP, Snibson KJ, Edwards S, Pearse M, Quinn C, and Sutton P: Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol. 2008;1:489-496.
37. Vujanic A, Wee JL, Snibson KJ, Edwards S, Pearse M, Quinn C, Moloney M, Taylor S, Scheerlinck JP, and Sutton P: Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine. 2010;28:2593-2597.
38. Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, Pasquier M, Simeoni E, van der Vlies AJ, McKinney JD, Hubbell JA, and Swartz MA: Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011;29:6959-6966.
39. Smith DJ, Bot S, Dellamary L, and Bot A: Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine. 2003;21:2805-2812.
40. Audouy SA, van der Schaaf G, Hinrichs WL, Frijlink HW, Wilschut J, and Huckriede A: Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine. 2011;29:4345-4352.
41. Kisich KO, Higgins MP, Park I, Cape SP, Lindsay L, Bennett DJ, Winston S, Searles J, and Sievers RE: Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation. Vaccine. 2011;29:905-912.
42. Lin WH, Griffin DE, Rota PA, Papania M, Cape SP, Bennett D, Quinn B, Sievers RE, Shermer C, Powell K, Adams RJ, Godin S, and Winston S: Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci USA. 2011;108:2987-2992.
43. Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, Derousse J, Germishuizen WA, Goonesekera S, Elbert K, Bloom BR, Miller R, Fourie PB, Hickey A, and Edwards D: Immunization by a bacterial aerosol. Proc Natl Acad Sci USA. 2008;105:4656-4660.
44. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon JK, Wang C, Hickey AJ, and Edwards D: Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010;12:330-337.
45. Thomas C, Rawat A, Bai S, and Ahsan F: Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J Pharm Sci. 2008;97:1213-1223.
46. Muttil P, Pulliam B, Garcia-Contreras L, Fallon JK, Wang C, Hickey AJ, and Edwards DA: Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 2010;12:699-707.
47. Cutts FT, Clements CJ, and Bennett JV: Alternative routes of measles immunization: a review. Biologicals. 1997;25:323-338.
48. Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, and Sepulveda-Amor J: Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ. 2002;80:806-812.
49. Castro JF, Bennett JV, Rincon HG, Munoz MT, Sanchez LA, and Santos JI: Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine. 2005;23: 1079-1084.
50. Wong-Chew RM, Islas-Romero R, Garcia-Garcia Mde L, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, and Valdespino-Gomez JL: Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine. 2006;24:683-690.
51. Dilraj A, Cutts FT, de Castro JF, Wheeler JG, Brown D, Roth C, Coovadia HM, and Bennett JV: Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet. 2000; 355:798-803.
52. Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, Ponci F, and De Grandi P: Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine. 2005;23:3634-3641.
53. Gordon SB, Malamba R, Mthunthama N, Jarman ER, Jambo K, Jere K, Zijlstra EE, Molyneux ME, Dennis J, and French N: Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses. Vaccine. 2008;26:5400-5406.
54. Dilraj A, Sukhoo R, Cutts FT, and Bennett JV: Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine. 2007;25:4170-4174.
55. de Vries RD, Stittelaar KJ, Osterhaus AD, and de Swart RL: Measles vaccination: new strategies and formulations. Expert Rev Vaccines. 2008;7:1215-1223.
56. LiCalsi C, Maniaci MJ, Christensen T, Phillips E, Ward GH, and Witham C: A powder formulation of measles vaccine for aerosol delivery. Vaccine. 2001;19:2629-2636.
57. Holmgren J, and Czerkinsky C: Mucosal immunity and vaccines. Nat Med. 2005;11:S45-S53.
58. Weiser JN, Markiewicz Z, Tuomanen EI, and Wani JH: Relationship between phase variation in colony morphology, intrastrain variation in cell wall physiology, and nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun. 1996;64:2240-2245.
59. Weiser JN, Bae D, Epino H, Gordon SB, Kapoor M, Zenewicz LA, and Shchepetov M: Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae. Infect Immun. 2001;69:5430-5439.
60. Lu D, and Hickey AJ: Pulmonary vaccine delivery. Expert Rev Vaccines. 2007;6:213-226.
61. Saluja V, Amorij JP, Kapteyn JC, de Boer AH, Frijlink HW, and Hinrichs WL: A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release. 2010;144:127-133.
62. LiCalsi C, Christensen T, Bennett JV, Phillips E, and Witham C: Dry powder inhalation as a potential delivery method for vaccines. Vaccine. 1999;17:1796-1803.
63. Fourie PB, Germishuizen WA, Wong YL, and Edwards DA: Spray drying TB vaccines for pulmonary administration. Expert Opin Biol Ther. 2008;8:857-863.
64. Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P, Pathak P, Rebits LG, and Sievers RE: Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv. 2008;21: 25-34.
65. Khatri L, Taylor KM, Craig DQ, and Palin K: An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions. Int J Pharm. 2001;227:121-131.